On Monday, Candel Therapeutics Inc (NASDAQ: CADL) opened lower -10.37% from the last session, before settling in for the closing price of $8.87. Price fluctuations for CADL have ranged from $1.16 to $14.60 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
It was noted that within the last five years, the titan of the Healthcare sector saw sales slided by -25.00%. Company’s average yearly earnings per share was noted -21.37% at the time writing. With a float of $27.51 million, this company’s outstanding shares have now reached $32.13 million.
The extent of productivity of a business whose workforce counts for 42 workers is very important to gauge. In terms of profitability, gross margin is 54.28%, operating margin of -2001.58%, and the pretax margin is -2939.13%.
Candel Therapeutics Inc (CADL) Insider Updates
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Candel Therapeutics Inc is 38.15%, while institutional ownership is 16.07%. The most recent insider transaction that took place on Dec 16 ’24, was worth 7,500,000. In this transaction Director of this company bought 1,250,000 shares at a rate of $6.00, taking the stock ownership to the 1,303,752 shares. Before that another transaction happened on Nov 29 ’24, when Company’s Chief Technology Officer sold 20,392 for $4.56, making the entire transaction worth $92,898. This insider now owns 125,657 shares in total.
Candel Therapeutics Inc (CADL) Performance Highlights and Predictions
Wall Street market experts anticipate that the next fiscal year will bring earnings of 0 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -21.37% per share during the next fiscal year.
Candel Therapeutics Inc (NASDAQ: CADL) Trading Performance Indicators
Check out the current performance indicators for Candel Therapeutics Inc (CADL). In the past quarter, the stock posted a quick ratio of 1.18.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.74, a number that is poised to hit -0.27 in the next quarter and is forecasted to reach -1.35 in one year’s time.
Technical Analysis of Candel Therapeutics Inc (CADL)
The latest stats from [Candel Therapeutics Inc, CADL] show that its last 5-days average volume of 2.03 million was inferior to 2.42 million than last year’s volume. As of the previous 9 days, the stock’s Stochastic %D was 61.68%. Additionally, its Average True Range was 1.39.
During the past 100 days, Candel Therapeutics Inc’s (CADL) raw stochastic average was set at 38.51%, which indicates a significant increase from 34.68% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 349.61% in the past 14 days, which was higher than the 148.92% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $5.75, while its 200-day Moving Average is $6.27. Now, the first resistance to watch is $8.63. This is followed by the second major resistance level at $9.31. The third major resistance level sits at $9.69. If the price goes on to break the first support level at $7.57, it is likely to go to the next support level at $7.20. Assuming the price breaks the second support level, the third support level stands at $6.52.
Candel Therapeutics Inc (NASDAQ: CADL) Key Stats
There are currently 32,476K shares outstanding in the company with a market cap of 342.01 million. Presently, the company’s annual sales total 0 K according to its annual income of -37,940 K. Last quarter, the company’s sales amounted to 0 K and its income totaled -10,650 K.
